Abstract
<strong>Background:</strong> Remdesivir has shown a positive impact on patient’s clinical improvement with COVID-19 and could represent and future viral infections. <strong>Results:</strong> 16 out of 37 patients presented bradycardia, 4 of these patients had QTc > 450 ms. Infusion for 3 days or more of infusion had a higher incidence of bradycardia (12 vs 4 patients). Overall, patients without bradycardia had a longer hospitalization (20.5 vs 15.5 days); 7 patients died, 2 of them had bradycardia. <strong>Conclusion:</strong> Our results have shown clear evidence of bradycardia after remdesivir infusion. Prospective, double-blinded, and randomized studies with an evident representative sample size with various ethnicities and races are highly needed earlier than later to establish these important findings.
Highlights
Remdesivir is a nucleoside analog used against several RNA-dependent RNA polymerase viruses, affecting their replication and resulting in the early termination of the viral cycle, and it has shown a positive impact in clinical improvement of patients with COVID-19 [1, 2]
We faced one of the worst pandemics in history, and possible recurrent waves could be expected, which is why we performed this retrospective study to establish the relationship of remdesivir with cardiac arrhythmias
To establish the relationship of remdesivir with cardiac arrhythmias in COVID-19, as well as to determine its relationship with cardiac arrest in COVID-19. This is a descriptive retrospective study establishing the relationship of remdesivir with cardiac arrhythmias and determining the relationship between remdesivir and cardiac arrest
Summary
Remdesivir is a nucleoside analog used against several RNA-dependent RNA polymerase viruses, affecting their replication and resulting in the early termination of the viral cycle, and it has shown a positive impact in clinical improvement of patients with COVID-19 [1, 2]. There is clear evidence of the broad-spectrum antiviral activity of remdesivir via mediation of RNA synthesis inhibition in coronaviruses [3]. This medication has been associated with cardiac arrhythmias and events after its administration [4, 5]. Remdesivir has shown a positive impact on patient’s clinical improvement with COVID-19 and could represent and future viral infections
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
